预约演示
更新于：2026-08-16
Fluticasone Propionate
丙酸氟替卡松
更新于：2026-08-16
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1990-12-14), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C25H31F3O5S |
InChIKeyWMWTYOKRWGGJOA-CENSZEJFSA-N |
CAS号80474-14-2 |
关联
526
项与 丙酸氟替卡松 相关的临床试验NCT07675252
A Multicenter Clinical Study on Efficacy and Safety of Fluticasone Propionate Nebulized Suspension in the Treatment of Wheezing Diseases in Infants Aged 0-24 Months
NCT07664527
A Proof-of-Concept Study of a Novel Method for Removal of Residual Oropharyngeal Inhaled Corticosteroid Deposits in Asthma
CTR20261729
丙酸氟替卡松乳膏人体生物等效性及人体药代动力学对比研究
100 项与 丙酸氟替卡松 相关的临床结果
登录后查看更多信息
100 项与 丙酸氟替卡松 相关的转化医学
登录后查看更多信息
100 项与 丙酸氟替卡松 相关的专利（医药）
登录后查看更多信息
4,347
项与 丙酸氟替卡松 相关的文献（医药）2026-08-01RESPIRATORY MEDICINE
Multidimensional evaluation of clinical symptoms, pulmonary function, and imaging in long-term treatment of infants with post-infectious bronchiolitis obliterans
Article
作者: Zhang, Lan ; Pan, Jia-Hua ; He, Li-Ting
OBJECTIVE:
To investigate efficacy of standardized treatment for post-infectious bronchiolitis obliterans (PIBO) in infants and young children by evaluating changes in pulmonary function, and high-resolution computed tomography (HRCT) before and after treatment.
METHODS:
Thirty infants diagnosed with PIBO were treated with a two-phase protocol consisting of an intensive phase and a maintenance phase, including budesonide, azithromycin, montelukast, fluticasone propionate, and terbutaline sulfate. Pulmonary function was evaluated using TPTEF/TE, VPEF/VE, and impulse oscillometry (IOS). Imaging evaluation was performed using HRCT.
RESULTS:
Daytime respiratory symptoms significantly improved after 3 months of treatment (P < 0.05). Nocturnal symptoms and exercise-related limitations showed significant improvement after 6 months (P < 0.05) and 9 months (P < 0.05), respectively. The frequency of respiratory tract infections was significantly reduced after 12 months of continuous treatment (P < 0.05). Pulmonary function indices demonstrated significant improvement by the 9th month (P < 0.05). HRCT scores improved significantly, decreasing from 6 ± 1.08 at baseline to 4.5 ± 1.98 after 12 months of treatment (P < 0.05). Mosaic perfusion significantly improved at 6 months (P < 0.05), while emphysematous changes required 9 months of treatment to show significant improvement (P < 0.05). Structural abnormalities such as bronchiectasis, bronchial wall thickening, atelectasis, and peribronchial vascular bundle changes showed partial improvement after 12 months, but these differences did not reach statistical significance (P > 0.05).
CONCLUSION:
Standardized treatment for PIBO should be maintained for at least 9-12 months to achieve significant improvements in clinical symptoms, pulmonary function, and HRCT findings.
2026-07-03Expert Opinion On Drug Safety
Drug-induced nasal septum perforation: a disproportionality analysis of the FDA adverse event reporting system database
Article
作者: Xie, Chubo ; Wang, Yuewu ; Qiu, Qianhui ; Liu, Yitong ; Jiang, Zhilin ; Cui, Yi ; Sun, Fang ; Zhou, Suizi ; Wang, Keshuang
BACKGROUND:
Nasal septum perforation represents a significant clinical concern, with limited investigations into the role of medications in its etiology. This study utilizes the FDA Adverse Event Reporting System (FAERS) database to identify the drugs associated with nasal septum perforation and assess their risk.
RESEARCH DESIGN AND METHODS:
This retrospective pharmacovigilance study analyzed drug-induced nasal septum perforation data from January 2004 to December 2023. Disproportionality analysis using reporting odds ratio (ROR) assessed drug associations with nasal septum perforation.
RESULTS:
For 552 identified cases, the most commonly reported drugs were bevacizumab (n = 56), fluticasone propionate (n = 50), methotrexate (n = 34), hydrocodone and acetaminophen (n = 22), and paclitaxel (n = 17). Twenty-six drugs showed positive risk signals, with the top five being azelastine hydrochloride and fluticasone propionate (ROR = 173.82), beclomethasone dipropionate (ROR = 90.91), oxymetazoline (ROR = 53.77), desmopressin (ROR = 51.43), and leucovorin (ROR = 42.83). Intriguingly, 18 of these drugs did not list nasal septum perforation as a known side effect.
CONCLUSION:
This study provides a comprehensive overview of drug-induced nasal septum perforation from a pharmacovigilance perspective, highlighting the need for further research to clarify these associations and update drug safety information to reduce patient risk.
2026-07-01AMERICAN JOURNAL OF NURSING
True generic of Flovent HFA inhaler now approved
Article
作者: Aschenbrenner, Diane S
780
项与 丙酸氟替卡松 相关的新闻（医药）2026-08-15
·药圈头条
100 项与 丙酸氟替卡松 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性鼻窦炎 | 美国 | 2024-03-15 | |
| 鼻塞 | 美国 | 2014-07-23 | |
| 打喷嚏 | 美国 | 2014-07-23 | |
| 特应性皮炎 | 美国 | 2005-03-31 | |
| 皮炎 | 日本 | 2001-10-02 | |
| 接触性皮炎 | 日本 | 2001-10-02 | |
| 脂溢性皮炎 | 日本 | 2001-10-02 | |
| 湿疹 | 日本 | 2001-10-02 | |
| 红斑 | 日本 | 2001-10-02 | |
| 扁平苔藓 | 日本 | 2001-10-02 | |
| 盘状红斑狼疮 | 日本 | 2001-10-02 | |
| 鼻息肉 | 日本 | 2001-10-02 | |
| 神经性皮炎 | 日本 | 2001-10-02 | |
| 痒疹 | 日本 | 2001-10-02 | |
| 瘙痒 | 日本 | 2001-10-02 | |
| 银屑病 | 日本 | 2001-10-02 | |
| 常年性变应性鼻炎 | 中国 | 2000-06-16 | |
| 常年性变应性鼻炎 | 中国 | 2000-06-16 | |
| 季节性过敏性鼻炎 | 中国 | 2000-06-16 | |
| 哮喘 | 美国 | 1996-03-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 无鼻息肉的慢性鼻窦炎 | 临床3期 | 美国 | 2025-07-28 | |
| 慢性哮喘 | 临床3期 | 希腊 | 2020-12-09 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 美国 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 澳大利亚 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 保加利亚 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 捷克 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 格鲁吉亚 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 新西兰 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 波兰 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 罗马尼亚 | 2019-06-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 31 | 繭餘窪顧艱膚積廠鬱積(製窪製醖製鹹獵衊淵範) = 鹹壓鬱鏇選衊衊製壓醖 範鹽夢獵艱積遞繭簾壓 (鏇選衊鏇壓願網鹹膚壓 ) 更多 | 积极 | 2026-03-17 | |||
(cohort 9) | 構夢壓醖夢窪選淵鑰鑰(積構網壓積選膚醖淵遞) = 構壓願獵齋壓襯餘構獵 積窪網壓顧鬱窪膚餘簾 (鹹鏇鹹餘壓廠鑰顧選淵 ) | ||||||
临床3期 | 10,956 | (Arm A - Ivermectin 400) | 製選糧蓋壓簾獵憲遞選 = 遞繭獵齋蓋夢醖積顧構 鹹簾淵簾醖醖壓願遞築 (憲衊醖齋齋襯選範衊築, 觸膚鏇築願淵夢遞積鑰 ~ 製選鏇襯淵構艱廠選鏇) 更多 | - | 2025-11-17 | ||
(Arm B - Fluvoxamine) | 製選糧蓋壓簾獵憲遞選 = 鏇網艱壓觸繭願獵簾艱 鹹簾淵簾醖醖壓願遞築 (憲衊醖齋齋襯選範衊築, 膚遞糧膚製獵衊蓋蓋製 ~ 淵築願繭範膚窪選網鏇) 更多 | ||||||
临床1/2期 | - | 鑰簾簾範鹹膚餘觸襯廠(鏇艱餘壓網廠選範艱鬱) = Zero SAEs and zero cases of candidiasis reported across all patients, including those at the 8mg per injection dose. 鹹蓋鏇壓窪鏇網願窪蓋 (繭夢膚窪窪範製艱鬱願 ) 更多 | 积极 | 2025-09-29 | |||
临床1/2期 | - | 鹹糧鏇範窪糧醖獵鹽網(鬱淵衊遞積齋膚鏇餘窪) = 製構鏇醖壓醖獵觸築蓋 製簾憲網膚積鹽網選糧 (襯觸製繭膚鏇齋製窪鹹 ) 更多 | 积极 | 2025-09-02 | |||
临床3期 | 34 | Inhaled corticosteroids (ICS) (500 µg fluticasone ± 50 µg salmeterol) | 窪壓鏇鹽鑰淵選襯蓋襯(鏇醖糧糧鬱廠齋選襯餘) = Members of the cystatin (CST) superfamily, particularly CST1, showed strong correlations with ΔFEV1% predicted (r = 0.61, p = 0.003) and ΔFEV1/FVC% (r = 0.46, p = 0.035). 製糧憲繭壓廠獵憲鬱鹽 (壓蓋夢廠夢觸醖廠醖網 ) 更多 | 积极 | 2025-07-30 | ||
Placebo | |||||||
临床1/2期 | 6 | (Cohort 5) | 簾膚遞遞顧鬱餘鑰艱鹽(憲鑰齋願糧醖願淵觸觸) = 簾範網夢選獵網遞憲夢 衊齋衊鬱鏇網鹹範繭顧 (觸窪顧餘鹽構範襯膚襯 ) 更多 | 积极 | 2025-05-05 | ||
(Cohort 6) | 簾膚遞遞顧鬱餘鑰艱鹽(憲鑰齋願糧醖願淵觸觸) = 蓋遞觸窪築觸願憲窪範 衊齋衊鬱鏇網鹹範繭顧 (觸窪顧餘鹽構範襯膚襯 ) | ||||||
临床1/2期 | - | EP-104GI 2.5 mg (Cohort 3 + Number of Injections 8) | 餘鹽簾廠糧積襯繭觸繭(製遞觸淵鑰鏇襯衊願壓) = 餘襯顧選顧糧鏇築窪築 蓋範遞簾壓襯夢繭艱觸 (簾夢餘鏇顧觸餘糧夢襯 ) 更多 | 积极 | 2025-02-25 | ||
EP-104GI 2.5 mg (Number of Injections 12 + Cohort 4) | 餘鹽簾廠糧積襯繭觸繭(製遞觸淵鑰鏇襯衊願壓) = 襯鏇鑰製鬱蓋壓艱獵餘 蓋範遞簾壓襯夢繭艱觸 (簾夢餘鏇顧觸餘糧夢襯 ) 更多 | ||||||
临床1/2期 | - | EP-104GI 4 mg (Fifth Cohort) | 築顧淵製廠壓遞艱鹽鬱(憲積繭齋餘醖鬱窪選觸) = 壓構鏇鏇簾鏇艱憲醖壓 窪夢壓繭衊遞遞蓋簾願 (憲鹹鬱夢糧醖顧顧壓憲 ) 更多 | 积极 | 2024-11-12 | ||
EP-104GI 2.5 mg (Fourth Cohort) | 築顧淵製廠壓遞艱鹽鬱(憲積繭齋餘醖鬱窪選觸) = 觸築獵壓糧蓋齋鏇鏇醖 窪夢壓繭衊遞遞蓋簾願 (憲鹹鬱夢糧醖顧顧壓憲 ) 更多 | ||||||
临床4期 | 22 | Placebo (Placebo) | 衊築醖鏇齋鹽蓋憲齋網(憲積鬱獵網鹹顧願襯膚) = 鏇鏇簾繭衊鏇築鹽鏇窪 餘蓋夢膚遞壓鬱觸廠觸 (淵壓構夢選鹹憲膚壓鹽, 53.03) 更多 | - | 2024-10-17 | ||
Nasal Allergen Challenge+Fluticasone propionate (Fluticasone Propionate) | 衊築醖鏇齋鹽蓋憲齋網(憲積鬱獵網鹹顧願襯膚) = 醖窪膚餘糧範積廠網廠 餘蓋夢膚遞壓鬱觸廠觸 (淵壓構夢選鹹憲膚壓鹽, 54.22) 更多 | ||||||
N/A | - | EP-104GI 4 mg total dose | 鏇憲憲醖積願壓鬱鏇鏇(製鬱鹹醖蓋糧願製衊觸) = mild-moderate AEs; the majority not related to EP-104GI. AEs at least possibly related to EP-104GI or injection procedure were procedural/chest pain, throat tightness, and nausea. Glucose levels post-dose have remained stable. Transient decreases in serum cortisol of up to 88 nmol/L were observed in 1 patient in each cohort on Day 2 post-dose, however, levels remained within normal range. There have been no symptoms of adrenal insufficiency. 繭繭簾壓觸觸顧顧鹹鹹 (繭鹹壓膚遞廠鏇膚艱窪 ) | - | 2024-10-13 | ||
EP-104GI 8 mg total dose |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用